AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34165503 — intervention group
Group type: COMPARATOR
Intervention: T-DM1 (trastuzumab emtansine)
Number of subjects: 202
Study 35128627 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalloped bleaching tray cutout
Number of subjects: 120
Study 35128627 — intervention group
Group type: COMPARATOR
Intervention: Nonscalloped bleaching tray cutout
Number of subjects: 120
Study 35128627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (scalloped and nonscalloped)
Number of subjects: 120
Study 33234048 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert physical therapist (PT) as reference standard for joint mobilization
Number of subjects: 24
Study 35742445 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS plus SFE
Number of subjects: 68
Study 35742445 — intervention group
Group type: COMPARATOR
Intervention: SFE alone (with sham TENS)
Number of subjects: 68
Study 34378517 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporarily Implanted Nitinol Device (iTind)
Number of subjects: 0
Study 34378517 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 32567941 — intervention group
Group type: EXPERIMENTAL
Intervention: Triticum vulgare (TV) spray, gluten-free, used twice daily after toothbrushing for 2 weeks
Number of subjects: 57
Study 32567941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TV spray), enrolled in a mechanical plaque control programme for 2 weeks
Number of subjects: 57
Study 33768368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Dry Powder Inhaler A-4.5 (500 μg)
Number of subjects: 24
Study 33768368 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate Dry Powder Inhaler B-3.8 (500 μg)
Number of subjects: 24
Study 33768368 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate Dry Powder Inhaler C-3.7 (500 μg)
Number of subjects: 24
Study 35836147 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and intermittent hypoxia
Number of subjects: 20
Study 35836147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33560777 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexor (KF) eccentric exercise
Number of subjects: 52
Study 33560777 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor (KE) eccentric exercise
Number of subjects: 52
Study 33560777 — intervention group
Group type: COMPARATOR
Intervention: Control group performing elbow flexor (EF) MaxEC
Number of subjects: 52
Study 32301372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) initiated early postoperatively, training at 85‐90% of maximal capacity for 8‐10 weeks (4 × 5 repetitions).
Number of subjects: 42
Study 34472736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-based scalp block and laryngotracheal local anesthesia
Number of subjects: 40
Study 34472736 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 40
Study 36001881 — intervention group
Group type: EXPERIMENTAL
Intervention: Badges awarded
Number of subjects: 777
Study 36001881 — intervention group
Group type: EXPERIMENTAL
Intervention: Badges not awarded
Number of subjects: 777
Study 36001881 — intervention group
Group type: COMPARATOR
Intervention: No badges (control)
Number of subjects: 777
Study 33462512 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g per day)
Number of subjects: 14
Study 33462512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 32936580 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation, whole-heart motion correction algorithm (MC2)
Number of subjects: 42
Study 32936580 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation coronary artery motion correction algorithm (MC1)
Number of subjects: 42
Study 32936580 — intervention group
Group type: COMPARATOR
Intervention: Standard algorithm (STD)
Number of subjects: 42
Study 35413431 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional multimodal sleep pathway including nursing‐directed nonpharmacologic measures, low‐dose zolpidem and melatonin at bedtime.
Number of subjects: 125
Study 35413431 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional multimodal sleep pathway
Number of subjects: 125
Study 35413431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventional multimodal sleep pathway)
Number of subjects: 125
Study 34509197 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly once per week starting between 16 and 24 weeks of gestation until delivery, stillbirth, or reaching term (37 weeks)
Number of subjects: 800
Study 34509197 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered in the same manner as 17P
Number of subjects: 800
Study 32084053 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free group therapy
Number of subjects: 331
Study 32084053 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 331
Study 34921572 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CEM ONE (GCO)
Number of subjects: 120
Study 34921572 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CEM ONE Adhesive Enhancing Primer (GCO-AEP) + GCO
Number of subjects: 120
Study 34921572 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Universal (RXU)
Number of subjects: 120
Study 34921572 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Plus (SUP) + RXU
Number of subjects: 120
Study 34921572 — intervention group
Group type: EXPERIMENTAL
Intervention: G-MultiPrimer (GMP) + GCO
Number of subjects: 120
Study 34921572 — intervention group
Group type: EXPERIMENTAL
Intervention: SUP + RXU
Number of subjects: 120
Study 34658589 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 4614
Study 35989328 — intervention group
Group type: EXPERIMENTAL
Intervention: EV1000 group
Number of subjects: 40
Study 35989328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 34113979 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-for-age z-score (HAZ) at 2 years
Number of subjects: 1579
Study 34113979 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster height gain between 2 and 7 years
Number of subjects: 1579
Study 34113979 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-mass-index z-score (BMIZ) at 2 years
Number of subjects: 1579
Study 34113979 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional weight gain between 2 and 7 years
Number of subjects: 1579
Study 35380121 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32089359 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731
Study 32089359 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 731
Study 34694401 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) (n = 667)
Number of subjects: 1188
Study 34694401 — intervention group
Group type: COMPARATOR
Intervention: No caloric restriction (NoCR) (n = 521)
Number of subjects: 1188
Study 34694401 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 1188
Study 32367115 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-based fortifier (HMBF)
Number of subjects: 64
Study 32367115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk-based fortifier (BMBF)
Number of subjects: 64
Study 32367115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 34540645 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5% 20 mL (Control)
Number of subjects: 117
Study 34540645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 20 mL plus 4mg dexamethasone
Number of subjects: 117
Study 34540645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 20 mL plus 75 mcg dexmedetomidine
Number of subjects: 117
Study 32646850 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI-targeted biopsy
Number of subjects: 252
Study 34366227 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Health Literacy Screen (BHLS)
Number of subjects: 460
Study 34366227 — intervention group
Group type: COMPARATOR
Intervention: Newest Vital Sign (NVS)
Number of subjects: 460
Study 36460919 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective removal to soft dentin with calcium silicate-based material (CS)
Number of subjects: 134
Study 36460919 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective removal to soft dentin without calcium silicate-based material (CS)
Number of subjects: 134
Study 36460919 — intervention group
Group type: COMPARATOR
Intervention: Selective removal to firm dentin (control)
Number of subjects: 134
Study 36460919 — intervention group
Group type: COMPARATOR
Intervention: Pulp exposure (PE) group
Number of subjects: 134
Study 33649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical deep learning model using transfer learning with small datasets
Number of subjects: 954
Study 33649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical deep learning model
Number of subjects: 954
Study 33649375 — intervention group
Group type: COMPARATOR
Intervention: Flat classification method
Number of subjects: 954
Study 32096324 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium: YAG (Er:YAG) laser with RecoSMA technology
Number of subjects: 112
Study 35469957 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT AV DCB
Number of subjects: 330
Study 35469957 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated PTA
Number of subjects: 330
Study 32993775 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAT group (Cognitive-behavioral family therapy)
Number of subjects: 48
Study 32993775 — intervention group
Group type: COMPARATOR
Intervention: TAU group (treatment-as-usual)
Number of subjects: 48
Study 34112180 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based rad-score for predicting pathological complete response (pCR)
Number of subjects: 177
Study 34112180 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based rad-score for predicting pCR
Number of subjects: 177
Study 34112180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of CT- and MRI-based radiomic signatures
Number of subjects: 177
Study 32624472 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced imaging strategy (radiographs at 6 and 12 weeks only for clinical indication)
Number of subjects: 341
Study 32624472 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine radiography at 1, 2, 6 and 12 weeks)
Number of subjects: 341
Study 32624472 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced imaging strategy
Number of subjects: 341
Study 32624472 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341
Study 32624472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 341
Study 33749294 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 448
Study 33749294 — intervention group
Group type: COMPARATOR
Intervention: Alcohol and Cannabis Education (ACE)
Number of subjects: 448
Study 35000949 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Premio Bond/self‐etch technique
Number of subjects: 70
Study 35000949 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Premio Bond/total‐etch technique
Number of subjects: 70
Study 35000949 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Premio Bond/selective‐etch technique
Number of subjects: 70
Study 35000949 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond/self‐etch technique
Number of subjects: 70
Study 35000949 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond/selective‐etch technique
Number of subjects: 70
Study 34229042 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training
Number of subjects: 60
Study 34229042 — intervention group
Group type: COMPARATOR
Intervention: Motor-cognitive dual-task training
Number of subjects: 60
Study 35412528 — intervention group
Group type: EXPERIMENTAL
Intervention: Overminus spectacles
Number of subjects: 386
Study 35412528 — intervention group
Group type: COMPARATOR
Intervention: Nonoverminus spectacles
Number of subjects: 386
Study 35412528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups combined
Number of subjects: 386
Study 34413169 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV7+Tet+IFA+polyICLC
Number of subjects: 50
Study 34413169 — intervention group
Group type: EXPERIMENTAL
Intervention: IFA-containing adjuvants
Number of subjects: 50
Study 34413169 — intervention group
Group type: COMPARATOR
Intervention: TLR agonists only
Number of subjects: 50
Study 34413169 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length LPV7
Number of subjects: 50
Study 34413169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tet
Number of subjects: 50
Study 34413169 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV7
Number of subjects: 50
Study 32795098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (n=40)
Number of subjects: 122
Study 32795098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (n=40)
Number of subjects: 122
Study 32795098 — intervention group
Group type: COMPARATOR
Intervention: Chewed Prasugrel (n=21)
Number of subjects: 122
Study 32795098 — intervention group
Group type: COMPARATOR
Intervention: Integral Prasugrel (n=21)
Number of subjects: 122
Study 34079520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 73
Study 34079520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 32345990 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 44
Study 32345990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 35762124 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy (BFR)
Number of subjects: 32
Study 35762124 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (CONTROL)
Number of subjects: 32
Study 32711800 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (200 mg) and tenofovir alafenamide (25 mg) daily
Number of subjects: 5387
Study 32711800 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) daily
Number of subjects: 5387
Study 32711800 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine and tenofovir alafenamide
Number of subjects: 5387
Study 32711800 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine and tenofovir disoproxil fumarate
Number of subjects: 5387
Study 32711800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 5387
Study 35181698 — intervention group
Group type: EXPERIMENTAL
Intervention: FePO4-NP (specific surface area 98 m2g-1)
Number of subjects: 0
Study 35181698 — intervention group
Group type: EXPERIMENTAL
Intervention: FePO4-NP (specific surface area 188 m2g-1)
Number of subjects: 0
Study 35181698 — intervention group
Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 0
Study 33485147 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal spring-loaded countermovement jumps
Number of subjects: 9
Study 33326434 — intervention group
Group type: EXPERIMENTAL
Intervention: End-effector gait robot (EEGR) rehabilitation program (200 steps, 3 times a day for 5 weekdays)
Number of subjects: 20
Study 33326434 — intervention group
Group type: EXPERIMENTAL
Intervention: End-effector gait robot (EEGR) rehabilitation program
Number of subjects: 20
Study 33326434 — intervention group
Group type: COMPARATOR
Intervention: Walker on floor (WF)
Number of subjects: 20
Study 35677967 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 116
Study 35677967 — intervention group
Group type: COMPARATOR
Intervention: Capillary Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 116
Study 34293528 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (IgPro20) at 0.2 g/kg
Number of subjects: 0
Study 34293528 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (IgPro20) at 0.4 g/kg
Number of subjects: 0
Study 34293528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32780166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (50 mg/kg, maximum single dose 3 g) and thiamine (200 mg) every 12 h for 48 h
Number of subjects: 111
Study 32780166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline with the same protocol)
Number of subjects: 111
Study 35617333 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (15 weeks, 3 times per week)
Number of subjects: 65
Study 35617333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study 34803068 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Self Management Knowledge Questionnaire scores
Number of subjects: 221
Study 36283897 — intervention group
Group type: EXPERIMENTAL
Intervention: 4vHPV vaccine
Number of subjects: 1680
Study 36283897 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 1680
Study 36283897 — intervention group
Group type: COMPARATOR
Intervention: Gardasil 4 (control)
Number of subjects: 1680
Study 33097017 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1
Number of subjects: 106
Study 33097017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 34435513 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg·kg‐1 caffeine (CAF)
Number of subjects: 28
Study 34435513 — intervention group
Group type: COMPARATOR
Intervention: 5 mg·kg‐1 placebo (PLA)
Number of subjects: 28
Study 35469973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop system (CamAPS FX)
Number of subjects: 33
Study 34928960 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma transfusion
Number of subjects: 105717
Study 35238725 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) belimumab 10 mg/kg dose Q2W for three doses, then 10 mg/kg Q4W thereafter
Number of subjects: 0
Study 35238725 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) belimumab 400 mg dose QW for four doses, then 200 mg QW thereafter
Number of subjects: 0
Study 35238725 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (both IV and SC)
Number of subjects: 0
Study 33406220 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly e‐mails with audiovisual links
Number of subjects: 120
Study 33406220 — intervention group
Group type: COMPARATOR
Intervention: Traditional communication (verbal and written instructions)
Number of subjects: 120
Study 33406220 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly text messages
Number of subjects: 120
Study 33406220 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 120
Study 33406220 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income (high)
Number of subjects: 120
Study 33406220 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' education (high)
Number of subjects: 120
Study 34320040 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification Program (IMP) - 5 sessions guiding benign interpretations
Number of subjects: 51
Study 34320040 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification Program (IMP)
Number of subjects: 51
Study 34320040 — intervention group
Group type: COMPARATOR
Intervention: Interpretation Control Condition (ICC)
Number of subjects: 51
Study 33291727 — intervention group
Group type: EXPERIMENTAL
Intervention: Video condition (n = 38)
Number of subjects: 133
Study 33291727 — intervention group
Group type: EXPERIMENTAL
Intervention: Static-sequential-permanent pictures condition (n = 36)
Number of subjects: 133
Study 33291727 — intervention group
Group type: COMPARATOR
Intervention: Static-simultaneous-permanent pictures condition (n = 30)
Number of subjects: 133
Study 33291727 — intervention group
Group type: COMPARATOR
Intervention: Static-sequential-transient pictures condition (n = 29)
Number of subjects: 133
Study 36337766 — intervention group
Group type: COMPARATOR
Intervention: CUPG
Number of subjects: 139
Study 36337766 — intervention group
Group type: COMPARATOR
Intervention: ACUG
Number of subjects: 139
Study 36337766 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRG
Number of subjects: 139
Study 34280843 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta treatment
Number of subjects: 50
Study 35613415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + mindfulness meditation (AE + MM)
Number of subjects: 32
Study 35613415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 32
Study 35613415 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 32
Study 33627334 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 200
Study 33627334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32242144 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 hydroxyvitamin D (25OHD) concentration
Number of subjects: 417580
Study 32242144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization models
Number of subjects: 417580
Study 32242144 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal effects of phenotypes on 25OHD concentration
Number of subjects: 417580
Study 34274955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 453
Study 34274955 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular events (CVE)
Number of subjects: 453
Study 32143730 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine metronomic chemotherapy
Number of subjects: 158
Study 32143730 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine conventional chemotherapy
Number of subjects: 158
Study 32143730 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival, safety, and quality of life
Number of subjects: 158
Study 35839452 — intervention group
Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel)
Number of subjects: 296
Study 35839452 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 296